Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Lilly is a large, diversified global pharmaceutical company with a core high-revenue portfolio.
|
$982.80B |
$1038.79
+0.56%
|
|
JNJ
Johnson & Johnson
Johnson & Johnson's portfolio includes multiple monoclonal antibody therapeutics (e.g., DARZALEX, CARVYKTI, TECVAYLI, TALVEY) across oncology and immunology.
|
$526.61B |
$218.68
-0.41%
|
|
ABBV
AbbVie Inc.
AbbVie directly commercializes monoclonal antibody therapeutics (e.g., Skyrizi) as a core immunology asset.
|
$378.66B |
$214.31
-0.33%
|
|
AZN
AstraZeneca PLC
AZN is a large-cap pharmaceutical company with a diversified, global drug portfolio and a robust R&D pipeline.
|
$292.61B |
$94.41
+0.44%
|
|
NVO
Novo Nordisk A/S
Novo Nordisk is a leading large-cap pharmaceutical company with blockbuster GLP-1 products Wegovy and Ozempic, a core driver of its revenue and growth.
|
$278.30B |
$62.34
+9.15%
|
|
MRK
Merck & Co., Inc.
The company markets vaccines (Capvaxive) and has historical Gardasil sales, making vaccines a core product category.
|
$271.83B |
$108.84
-1.92%
|
|
TMO
Thermo Fisher Scientific Inc.
Thermo Fisher provides companion diagnostics (e.g., Oncomine Dx tests) that inform targeted therapies.
|
$233.64B |
$618.87
-0.93%
|
|
ABT
Abbott Laboratories
Abbott competes in generic drug segments across emerging markets, aligning with the Generic Drugs theme within Established Pharmaceutical Products.
|
$211.92B |
$121.77
-1.43%
|
|
AMGN
Amgen Inc.
Amgen's portfolio includes monoclonal antibody therapeutics such as Repatha and tezepelumab (TEZSPIRE).
|
$177.88B |
$330.37
+0.10%
|
|
GILD
Gilead Sciences, Inc.
Trodelvy is a TROP2-targeted antibody-drug conjugate (ADC), a core oncology modality.
|
$154.99B |
$124.94
+3.03%
|
|
PFE
Pfizer Inc.
Pfizer's vaccines portfolio (e.g., Comirnaty and other RSV vaccines) is a core, revenue-driving product line.
|
$145.83B |
$25.67
-0.85%
|
|
VRTX
Vertex Pharmaceuticals Incorporated
Vertex is a large-cap pharma/biotech with a diversified, revenue-generating portfolio anchored by CFTR modulators and expanding pipeline.
|
$113.16B |
$441.61
+0.61%
|
|
BMY
Bristol-Myers Squibb Company
Milvexian and Iberdomide are oral small-molecule therapeutics, a major product category.
|
$112.48B |
$55.27
-2.38%
|
Showing page 1 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
